After-Hours Stock Movers 09/06: (AAOI) (PGNX) (CMG) Higher; (CASY) (PLAY) (SIGM) Lower (more...)
- Record-setting rally pushes on as S&P ends week up 3 percent
- Trump's Cohn Pick Most Bullish Sign Yet for Banks - Cowen
- Unusual 11 Mid-Day Movers: (IDXG) (INVN) (EBS) Higher; (SCON) (DTEA) (DLTH) Lower (more...)
- 21st Century Fox (FOXA) offers to acquire Sky for GBP10.75/share
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Today's After-Hours Movers:
Applied Optoelectronics, Inc. (Nasdaq: AAOI) 18.9% HIGHER; announced updated guidance for its third quarter ended Sept. 30, 2016. Revenue in the range of $63.0 million to $65.0 million, above the prior outlook of $56.0 million to $59.0 million. (The Street sees revenue of $58.2 million.) Non-GAAP fully diluted earnings per share in the range of $0.26 to $0.29, using a weighted-average fully diluted share count of approximately 18.0 million shares. This is above the prior outlook of $0.16 to $0.21 per share. (The Street sees EPS of $0.19.)
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) 10.7% HIGHER; Valeant Pharmaceuticals International, Inc. (NYSE: VRX) and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced the U.S. commercial launch of RELISTOR® (methylnaltrexone bromide) Tablets, which is now available for prescribing. RELISTOR Tablets (450 mg once daily) were approved by the U.S. Food and Drug Administration (FDA) for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain on July 19, 2016.
Casey's General Stores (NASDAQ: CASY) 7% LOWER; reported Q1 EPS of $1.70, $0.11 worse than the analyst estimate of $1.81. Revenue for the quarter came in at $1.97 billion versus the consensus estimate of $1.99 billion.
Dave & Buster's Entertainment (NASDAQ: PLAY) 6.7% LOWER; reported Q2 EPS of $0.50, $0.06 better than the analyst estimate of $0.44. Revenue for the quarter came in at $244.3 million versus the consensus estimate of $243.14 million. Comparable store sales increased 1.0% compared to an 11.0% increase. Dave & Buster's Entertainment reaffirmed FY2016 guidance.
Sigma Designs (NASDAQ: SIGM) 6.3% LOWER; reported Q2 EPS of $0.07, $0.06 better than the analyst estimate of $0.01. Revenue for the quarter came in at $61.3 million versus the consensus estimate of $61.19 million.
AMD (Nasdaq: AMD) 3.7% LOWER; announced that it intends to commence concurrent public offerings, subject to market and other conditions, of approximately $600 million of its common stock (the "Shares") and $450 million aggregate principal amount of its convertible senior notes due 2026 (the "New Notes"). AMD is offering all of the Shares and the New Notes. In addition, AMD expects to grant the underwriters a 30-day option to purchase up to approximately $90 million of additional shares of common stock at the public offering price and up to $67.5 million principal amount of additional convertible senior notes.
HealthEquity (NASDAQ: HQY) 3.7% HIGHER; reported Q2 EPS of $0.16, $0.03 better than the analyst estimate of $0.13. Revenue for the quarter came in at $44.2 million versus the consensus estimate of $43.38 million. GUIDANCE: HealthEquity sees FY2017 revenue of $174-178 million, versus prior guidance of $173-177 million and the consensus of $176.5 million.
Ollies Bargain Outlet Holdings, Inc. (Nasdaq: OLLI) 2.5% LOWER; announced that affiliates of CCMP Capital Advisors, LP (CCMP) intend to offer 13,725,798 shares of the Companys common stock, par value $0.001 per share (the Common Stock), in an underwritten public offering. The offering consists entirely of secondary shares to be sold by CCMP. CCMP will receive all of the proceeds from the offering.
Callon Petroleum Company (NYSE: CPE) 2% LOWER; announced that it has commenced, subject to market and other conditions, an underwritten public offering of 23,000,000 shares of its common stock by the Company. The Company expects to grant the underwriters an option to purchase up to an additional 3,450,000 shares of common stock from the Company. Proceeds from the offering are expected to be used to fund substantially all of the pending Plymouth Acquisition, as described in the Company's Report on Form 8-K filed with the Securities and Exchange Commission on September 6, 2016. If the pending Plymouth Acquisition is not consummated, the Company intends to use the net proceeds of this offering to fund a portion of its exploration and development activities and for general corporate purposes, which may include leasehold interest and property acquisitions, repayment of indebtedness and working capital.
Valeant Pharmaceuticals (NYSE: VRX) 1.2% HIGHER; Valeant and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced the U.S. commercial launch of RELISTOR® (methylnaltrexone bromide) Tablets, which is now available for prescribing. RELISTOR Tablets (450 mg once daily) were approved by the U.S. Food and Drug Administration (FDA) for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain on July 19, 2016.
Catalent, Inc. (NYSE: CTLT) 1.2% LOWER; announced the launch of a secondary public offering of its common stock. Certain stockholders of Catalent (the Selling Stockholders) are offering for sale to the public all of the approximately 19.0 million shares of Catalents common stock owned by them. Catalent is not offering any stock in this transaction and will not receive any proceeds from the sale of the shares by the Selling Stockholders.
Finisar Corporation (NASDAQ: FNSR) 1.6% HIGHER; up on AAOI raised guidance
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Third-Party Said Interested in PrivateBancorp (PVTB) as CIBC (CM) Deal is Delayed
- UBS Cuts Price Target on Restoration Hardware (RH) to $34 Following 3Q
- Instinet Reiterates Buy on Oracle (ORCL) Ahead of 2Q Earnings
Create E-mail Alert Related CategoriesSpecial Reports
Related EntitiesWilliam Ackman, Pershing Square Capital, CCMP Capital, After-Hours Movers, 13D, Earnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!